H2020Индивидуална стипендия2016–2019

HIT-LVAD · Understanding blood pressure and vascular haemodynamics in implanted Left Ventricular Assist Device patients.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2016-09-01 → 2019-08-31
Финансиране от ЕС: 251 858 €
Участници: 2
Схема: MSCA-IF-GF

Линиите свързват координатора с партньорите.

Накратко на български

Кръвното налягане и движението на кръвта се анализират при пациенти с имплантирани механични помпи за сърцето. Това помага да се разберат причините за усложнения като инсулти и стомашно-чревни кръвоизливи при хора без пулс.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Understanding blood pressure and vascular haemodynamics in implanted Left Ventricular Assist Device patients.

"Although the remarkable improvements in medical progress are considered a positive achievement, they also create new societal challenges. For example, more people survive events such as heart attacks, thereby increasing the number of older people at risk of developing “heart failure” (HF). Indeed, ~15 Mio people are at risk of HF in Europe, of which 600 000 – 750 000 require “advanced cardiac care” and ultimately a heart transplant. Since not enough donor hearts are available, the second-best option is the surgical implantation of a mechanical heart pump, a so-called left ventricular assist device (LVAD). Historically, the second-generation LVAD patients (2G-LVAD pts) have significantly improved the survival of patients with advance HF, despite producing continuous flow and ""humans with no pulse"". Unfortunately, patients can still develop serious complications such as gastrointestinal bleeding, right heart failure, and stroke, categorised as “haemodynamic issues”. For this reason, the HIT-LVAD project was initiated, with the overall aim to improve the current understanding of the physiology that underpins the drastically altered circulation in 2G-LVAD pts, thus assisting in explaining risk in those on non-pulsatile LVADs."

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Background: Advanced heart failure (HF) is a growing health problem in the European Union (EU). Consequently, a growing number of HF patients now depend on state-of-the-art continuous flow Left Ventricular Assist Devices (cf-LVAD) as a bridge to transplant or as a means of destination therapy. Since the introduction and usage of cf-LVAD’s rather than traditional pulsatile LVAD’s, survival rates have significantly improved. However, an increased number of side-effects, including stroke and microvascular bleeding, have been reported. Suggested mechanisms associated with these side effects is lack of pulsatile pressure and flow throughout the system, however there are currently no data on macro/micro haemodynamics in these patients.Objectives: Columbia University’s Medical Center (CUMC) has the largest cf-LVAD programme in the world and thus will enable recruitment and assessment of the largest cohort to date of cf-LVAD patients. The aim of the project is to provide 5 work packages (WP) to understand the consequences of decreased pulsatile blood pressure (BP) and flow haemodynamics in cf-LVAD patients, compared to HF patients and age matched controls. Protocol: WP1:Measurement of BP and haemodynamics in cf-LVAD patients, using a new innovative BP device. WP2:Measurement of microvascular flow profiles in cf-LVAD patients, HF patients and healthy controls, using transcranial Doppler ultrasound and high frequency retinal Doppler ultrasound. WP3:Validation of brachial BP in cf-LVAD patients. WP4:Development of an improved LVAD device. WP5:Re-integration and Transfer of Knowledge back into the EU.Outcome: The project will require the fellow to re-integrate and transfer ALL of the newly acquired knowledge and skills from the world leading institution of CUMC back to the host institution, local community, national and EU clinical and industrial partners. This will facilitate the fellow to become a leading European authority in haemodynamics associated with LVAD patients.

Оригинален текст от CORDIS (на английски).

Участници

CARDIFF METROPOLITAN UNIVERSITY · CARDIFFКоординаторОбединеното кралство
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK · New YorkСъединени щати